个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

The safety and efficacy of lenvatinib combined with TACE and PD-1 inhibitors (Len-TAP) versus TACE alone in the conversion resection for initially unresectable hepatocellular carcinoma: Interim results from a multicenter prospective cohort study

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：

收录情况： ◇ SCIE ◇ CPCI(ISTP)

作者：
Xiaoyun, Z.[1] ; Zhu, X.[1] ; Feng, X.[2] ; Han, W.[3] ; Yan, M-L.[4] ; Xie, F.[5] ; Zhang, S.[6] ; Zhang, Y.[7] ; Jiang, X.[8] ; Peng, W.[1] ; Li, C.[1] ; Lu, W.[1] ; Liu, C.[1] ; Li, Q.[9] ; Chen, W.[10] ; Cheng, S.[11] ; Wen, T.[1] ;
机构： [1]SCU Sichuan Univ, Liver Surg & Liver Transplantat Ctr, Huaxi Campus, Chengdu, Peoples R China [2]UESTC,Sichuan Canc Hosp & Inst,Dept Hepatobiliary Pancreat Surg,Affiliated Canc Hosp,Sch Med,Chengdu,Peoples R China [3]Beijing Luhe Hosp, Dept Hepatobiliary Pancreat Surg, Beijing, Peoples R China [4]Fujian Prov Hosp, Dept Hepatobiliary Pancreat Surg, Fuzhou, Peoples R China [5]NeiJiang first peoples Hosp, Dept Hepatobiliary Pancreat Surg, Neijiang, Peoples R China [6]Chengdu Second Peoples Hosp, Dept Hepatobiliary Pancreat Surg, Chengdu, Peoples R China [7]Sichuan Prov Peoples Hosp, Dept Hepatobiliary Pancreat Surg, Chengdu, Sichuan, Peoples R China [8]Yibing Second Hosp, Dept Hepatobiliary Pancreat Surg, Chengdu, Peoples R China [9]SCU Sichuan Univ, Dept Oncol, Huaxi Campus, Chengdu, Peoples R China [10]SCU Sichuan Univ, Dept Radiol, Huaxi Campus, Chengdu, Peoples R China [11]Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Liver Surg & Liver Transplantat Ctr, Shanghai, Shanghai, Peoples R China
出处：
DOI： 10.1016/j.annonc.2022.07.839
ISSN：
语种：
外文
被引次数：
WOS：
中科院(CAS)分区：
出版当年[2022]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
最新[2023]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
JCR分区：
出版当年[2022]版：
Q1 ONCOLOGY
最新[2023]版：
Q1 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2022版] 出版当年五年平均 出版前一年[2021版] 出版后一年[2023版]

第一作者：
第一作者机构： [1]SCU Sichuan Univ, Liver Surg & Liver Transplantat Ctr, Huaxi Campus, Chengdu, Peoples R China
推荐引用方式(GB/T 7714)：
Xiaoyun Z.,Zhu X.,Feng X.,et al.The safety and efficacy of lenvatinib combined with TACE and PD-1 inhibitors (Len-TAP) versus TACE alone in the conversion resection for initially unresectable hepatocellular carcinoma: Interim results from a multicenter prospective cohort study[J].ANNALS OF ONCOLOGY.2022,33(7):S870-S870.doi:10.1016/j.annonc.2022.07.839.
APA：
Xiaoyun, Z.,Zhu, X.,Feng, X.,Han, W.,Yan, M-L....&Wen, T..(2022).The safety and efficacy of lenvatinib combined with TACE and PD-1 inhibitors (Len-TAP) versus TACE alone in the conversion resection for initially unresectable hepatocellular carcinoma: Interim results from a multicenter prospective cohort study.ANNALS OF ONCOLOGY,33,(7)
MLA：
Xiaoyun, Z.,et al."The safety and efficacy of lenvatinib combined with TACE and PD-1 inhibitors (Len-TAP) versus TACE alone in the conversion resection for initially unresectable hepatocellular carcinoma: Interim results from a multicenter prospective cohort study".ANNALS OF ONCOLOGY 33..7(2022):S870-S870

资源点击量：46662 今日访问量：1 总访问量：3330 更新日期：2024-11-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号